Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMVFRC)

• Drug Name: Mavrilimumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMMVFRC

Molecule-Related Drug Atlas

Drug(s) Targeting GMCSFR-alpha (CSF2RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sargramostim	DMY0M8J	Bone marrow transplantation	QB63.6	Approved	[4]
B-cell lymphoma vaccine	DMBRFUQ	Follicular lymphoma	2A80	Preregistration	[5]
Pixykine	DMCA6BW	Human immunodeficiency virus infection	1C62	Phase 3	[6]
Molgramostim	DM2TNJ1	Autoimmune pulmonary alveolar proteinosis	CB04.31	Phase 3	[7]
AFTVac	DMD3XMG	Glioblastoma multiforme	2A00.0	Phase 2	[8]
GM-CSF cancer vaccine	DML6PO5	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
Leukemia cancer vaccine	DMIFGLY	Acute myeloid leukaemia	2A60	Phase 2	[9]
Myeloma cancer vaccine	DMO1XUK	Multiple myeloma	2A83	Phase 2	[9]
MOR-103	DMXVIQN	Multiple sclerosis	8A40	Phase 1/2	[10]
KH-901	DMR14VE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Drug(s) Targeting Granulocyte-macrophage colony-stimulating factor (CSF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talimogene Laherparepvec	DMKBW5C	Melanoma	2C30	Approved	[12]
Lenzilumab	DMSRIT4	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3 Trial	[13]
JX-594	DM5WCV4	Hepatocellular carcinoma	2C12.02	Phase 3	[14]
Cabiralizumab	DMGE058	Pancreatic cancer	2C10	Phase 2	[13]
KB002/003	DM60G5O	Rheumatoid arthritis	FA20	Phase 2	[15]
GSK3196165	DMEXKF4	Rheumatoid arthritis	FA20	Phase 2	[3]
KB-003	DM74KIM	Severe asthma	CA23	Phase 2	[16]
MT203	DM7I0MT	Plaque psoriasis	EA90.0	Phase 2	[17]
MORAb-022	DMM7TBO	Autoimmune diabetes	5A10	Phase 1	[18]
Autologous melanoma cell vaccine	DMARYFK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GMCSFR-alpha (CSF2RA)	TT6MP2Z	CSF2R_HUMAN	Not Available	[2]
Granulocyte-macrophage colony-stimulating factor (CSF2)	TTNYZG2	CSF2_HUMAN	Antagonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7785).
• [2] Clinical pipeline report, company report or official report of MedImmune (2011).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
• [5] Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
• [6] Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
• [7] Clinical pipeline report, company report or official report of gensci-china.
• [8] Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
• [10] MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.
• [11] Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
• [15] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [16] US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
• [17] GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
• [18] Clinical pipeline report, company report or official report of Morphotek.